Drug intelligence / Profile preview

[89Zr]Zr-DFO-ABDC2

Development stage: Preclinical
Lead developer: Shanghai Jiao Tong University
Modality: Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals

Overview

[89Zr]Zr-DFO-ABDC2: sourced facts only. name: "A VHH (C2)-targeting human CD47 and its albumin-binding derivative (ABDC2) were labeled with 68Ga or 89Zr, respectively." [PMID:37403817]; target: "A VHH (C2)-targeting human CD47 and its albumin-binding derivative (ABDC2) were labeled with 68Ga or 89Zr, respectively." [PMID:37403817]; developer: "Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China." [PMID:37403817]; stage: "Compared with [68Ga]Ga-NOTA-C2, [89Zr]Zr-DFO-ABDC2 had a significantly prolonged circulation time, increased tumor uptake, and reduced accumulation in the kidneys." [PMID:37403817]

Targets

CD47 (Cluster of Differentiation 47)

Beyond the preview

Go deeper on [89Zr]Zr-DFO-ABDC2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [89Zr]Zr-DFO-ABDC2.